Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Income from Non-Controlling Interests (2024 - 2025)

Coeptis Therapeutics Holdings has reported Income from Non-Controlling Interests over the past 2 years, most recently at -$675321.0 for Q4 2025.

  • Quarterly results put Income from Non-Controlling Interests at -$675321.0 for Q4 2025, down 125.81% from a year ago — trailing twelve months through Dec 2025 was $647241.0 (up 419.25% YoY), and the annual figure for FY2025 was -$360177.0, down 82.87%.
  • Income from Non-Controlling Interests for Q4 2025 was -$675321.0 at Coeptis Therapeutics Holdings, down from $159360.0 in the prior quarter.
  • Over the last five years, Income from Non-Controlling Interests for COEPW hit a ceiling of $799991.0 in Q2 2025 and a floor of -$675321.0 in Q4 2025.